47.33
-0.77 (-1.60%)
| 前收盘价格 | 48.10 |
| 收盘价格 | 48.77 |
| 成交量 | 956,668 |
| 平均成交量 (3个月) | 1,395,845 |
| 市值 | 5,437,416,960 |
| 价格/销量 (P/S) | 13.14 |
| 股市价格/股市净资产 (P/B) | 23.09 |
| 52周波幅 | |
| 利润日期 | 7 May 2026 |
| 稀释每股收益 (EPS TTM) | -2.55 |
| 总债务/股东权益 (D/E MRQ) | 20.22% |
| 流动比率 (MRQ) | 10.25 |
| 营业现金流 (OCF TTM) | -229.84 M |
| 杠杆自由现金流 (LFCF TTM) | -134.32 M |
| 资产报酬率 (ROA TTM) | -50.15% |
| 股东权益报酬率 (ROE TTM) | -106.71% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Scholar Rock Holding Corporatio | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -3.5 |
| 技术振荡指标 | 2.5 |
| 平均 | 0.63 |
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.35% |
| 机构持股比例 | 118.63% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 70.00 (BMO Capital, 47.90%) | 购买 |
| 中 | 58.00 (22.54%) | |
| 低 | 53.00 (Barclays, 11.98%) | 购买 |
| 平均值 | 58.67 (23.96%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 46.91 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BMO Capital | 04 Mar 2026 | 70.00 (47.90%) | 购买 | 47.43 |
| Barclays | 04 Mar 2026 | 53.00 (11.98%) | 购买 | 47.43 |
| Citigroup | 04 Mar 2026 | 58.00 (22.54%) | 购买 | 47.43 |
| Piper Sandler | 04 Mar 2026 | 58.00 (22.54%) | 购买 | 47.43 |
| Truist Securities | 04 Mar 2026 | 55.00 (16.21%) | 购买 | 47.43 |
| HC Wainwright & Co. | 03 Mar 2026 | 58.00 (22.54%) | 购买 | 44.31 |
| 26 Jan 2026 | 58.00 (22.54%) | 购买 | 44.89 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合